Frankenfield Christopher James
SEC CIK 1988344 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | CFO | 24.8K | — | $11.3K | 4 | 2025-01-01 | 2026-01-02 |
Most active insiders at XLO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Shannon James Samuel | Dir | $43.9K | — |
| 2 | Frankenfield Christopher James | CFO | — | $4,499 |
| 3 | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | — | $1,169 |
| 4 | Luptakova Katarina | Chief MEDICAL Off | — | — |
| 5 | Russo Rene | Pres AND CEO, Dir | — | — |
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-01-05 | 2026-01-02 | XLO | Xilio Therapeutics, Inc. | Frankenfield Christopher James | CFO | S - Sale+OE | $0.64 | -7,030 | 24.8K | -22% | -$4,499 |
| DT | 2026-01-05 | 2026-01-01 | XLO | Xilio Therapeutics, Inc. | Frankenfield Christopher James | CFO | M - OptEx | — | +19.4K | 31.8K | +156% | — |
| D | 2025-01-03 | 2025-01-01 | XLO | Xilio Therapeutics, Inc. | Frankenfield Christopher James | CFO | M - OptEx | — | +19.4K | 19.4K | New | — |
| D | 2025-01-03 | 2025-01-02 | XLO | Xilio Therapeutics, Inc. | Frankenfield Christopher James | CFO | S - Sale+OE | $0.98 | -6,954 | 12.4K | -36% | -$6,815 |
Purchase Sale Sale after option exercise All abbreviations